Overview

Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients

Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
First-in-humans, phase 1, dose-escalation study with 4 dose levels of single-agent IMO-2125.
Phase:
Phase 1
Details
Lead Sponsor:
Idera Pharmaceuticals, Inc.
Treatments:
Interferons
Ribavirin